Says well-positioned with ex-Humira platform for 2025. Sees clear runway for growth “for at least eight years.” Expects Skyrizi and Rinvoq to ...

AbbVie (ABBV) is reaffirming its expectations for a high single-digit compound annual revenue growth rate through 2029. This guidance assumes ...

Though it was often joined at the top of the list throughout the year by fellow AbbVie offering Rinvoq, that wasn’t the case in December, when Rinvoq fell two spots as its TV ad spending dropped ...